On this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with John Cassidy, CEO of Cambridge Cancer Genomics. CCG aims to transform oncology by combining liquid biopsy with genomics and artificial intelligence to predict disease progression and improve treatment.
Listen now to learn about the challenges with chemotherapy that CCG is tackling, the role that liquid biopsy and artificial intelligence play in their solution, and how their approach could forever change the way we treat cancer: